Key result
Early changes in basal longitudinal diastolic strain time during doxorubicin are linked to subsequent cardiotoxicity.
Why the study?
Diastolic dysfunction is common during cancer therapy, but whether it predicts systolic dysfunction remains unclear.
Does the change in longitudinal diastolic strain (Ds) time during doxorubicin therapy predict subsequent systolic dysfunction in patients with active breast cancer?
Cohort (n=69)
Does the change in longitudinal diastolic strain (Ds) time during doxorubicin therapy predict subsequent systolic dysfunction in patients with active breast cancer?
Early changes in longitudinal diastolic strain time during doxorubicin therapy can predict subsequent subclinical systolic dysfunction (GLS reduction) in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Ds may aid early cardiotoxicity detection in breast cancer; leaves open predictive value for systolic dysfunction pending validation.
Background: Although diastolic dysfunction is common among patients treated with cancer therapy, no clear evidence has been shown that it predicts systolic dysfunction. This study evaluated the correlation of longitudinal diastolic strain (Ds) with echocardiography diastolic parameters and to estimate its role in the early detection of cardiotoxicity among patients with active breast cancer. Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), a prospective registry enrolling all adult patients referred to the cardio-oncology clinic. All patients with breast cancer, planned for Doxorubicin therapy were included. Echocardiography, including Global longitudinal systolic strain (GLS) and Ds, was assessed at baseline before chemotherapy (T1), during Doxorubicin therapy (T2) and after the completion of Doxorubicin therapy (T3). Cardiotoxicity were determined by GLS relative reduction of ≥15%. Ds was assessed as the time of lengthening =diastolic time (ms) measured. Results: Among 69 patients, 67 (97.1%) were females with a mean age 52±13years. Diastolic strain time measurement was significantly associated with the standard diastolic parameters. Significant GLS reduction was observed in 10 (20%) patients at T3 . Both in a univariate and a multivariate analyses the change in Ds basal time from T1 to T2 emerged to be significantly associated with GLS reduction at T3 (p<0.04). Conclusions: Among breast cancer patients, Ds time showed high correlation to standard diastolic echocardiography parameters. Relative reduction in Ds basal time emerged associated with clinically significant systolic dysfunction as measured by GLS reduction.
No takes yet. Share an insight, caveat, or question.
Hochstadt et al. (2020) conducted a cohort in Active breast cancer (n=69). Change in longitudinal diastolic strain (Ds) basal time was evaluated on Cardiotoxicity (GLS relative reduction of ≥15% at T3) (p=<0.04). A change in longitudinal diastolic strain basal time during early doxorubicin therapy was associated with subsequent cardiotoxicity at treatment completion.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: